prednisone has been researched along with Ataxia in 22 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
Ataxia: Impairment of the ability to perform smoothly coordinated voluntary movements. This condition may affect the limbs, trunk, eyes, pharynx, larynx, and other structures. Ataxia may result from impaired sensory or motor function. Sensory ataxia may result from posterior column injury or PERIPHERAL NERVE DISEASES. Motor ataxia may be associated with CEREBELLAR DISEASES; CEREBRAL CORTEX diseases; THALAMIC DISEASES; BASAL GANGLIA DISEASES; injury to the RED NUCLEUS; and other conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Eligible subjects were randomized to receive twelve cycles of IVIG (IVIG+) or no IVIG (NO-IVIG) in addition to prednisone and neuroblastoma risk-adapted chemotherapy." | 9.27 | Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. ( Cohn, SL; de Alarcon, PA; Hogarty, MD; London, WB; Maris, JM; Matthay, KK; Naranjo, A; Panzer, JA; Park, JR; Tenney, SC, 2018) |
| "Seventy-nine patients with cyclosporine- and prednisone-dependent myasthenia gravis (MG) after thymectomy received tacrolimus for a mean of 2." | 9.11 | Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis. ( Armengol, M; Azem, J; Buera, M; Cervera, C; Fort, JM; López-Cano, M; Ponseti, JM; Vilallonga, R, 2005) |
| "Eligible subjects were randomized to receive twelve cycles of IVIG (IVIG+) or no IVIG (NO-IVIG) in addition to prednisone and neuroblastoma risk-adapted chemotherapy." | 5.27 | Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. ( Cohn, SL; de Alarcon, PA; Hogarty, MD; London, WB; Maris, JM; Matthay, KK; Naranjo, A; Panzer, JA; Park, JR; Tenney, SC, 2018) |
| "Seventy-nine patients with cyclosporine- and prednisone-dependent myasthenia gravis (MG) after thymectomy received tacrolimus for a mean of 2." | 5.11 | Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis. ( Armengol, M; Azem, J; Buera, M; Cervera, C; Fort, JM; López-Cano, M; Ponseti, JM; Vilallonga, R, 2005) |
| "Paroxysmal dysarthria-ataxia is a rare neurological condition due to ephaptic transmission, generally appearing in multiple sclerosis patients characterized by stereotyped attacks of slurred speech usually accompanied by ataxia, appearing many times a day." | 1.40 | Paroxysmal dysarthria-ataxia in remitting-relapsing Bickerstaff's-like encephalitis. ( Acler, M; Bonetti, B; Cerini, R; Fiaschi, A; Monaco, S; Piffer, S; Richelli, S; Turri, G, 2014) |
| "Opsoclonus-myoclonus-ataxia syndrome (OMA) in children is most commonly associated with occult neuroblastoma (NB)." | 1.33 | Late presentation of opsoclonus-myoclonus-ataxia syndrome in a child with stage 4S neuroblastoma. ( Johnston, DL; Mutch, LS, 2005) |
| "The ataxic form of chronic inflammatory demyelinating polyradiculoneuropathy (ataxic-CIDP) has been recently described as a subtype of chronic ataxic neuropathy, distinguished by steroid responsiveness and relative preservation of myelinated fibres at sural nerve biopsy." | 1.33 | Hyperpyrexia-triggered relapses in an unusual case of ataxic chronic inflammatory demyelinating polyradiculoneuropathy. ( Bertolasi, L; Ferrari, S; Mazzucco, S; Mezzina, C; Rizzuto, N; Tomelleri, G, 2006) |
| "Susac's syndrome is a rare disorder characterized by the triad of microangiopathy of the brain and retina with hearing loss." | 1.31 | Susac's syndrome: beneficial effects of corticosteroid therapy in a Japanese case. ( Hashimoto, Y; Tashima, K; Uchino, M; Uyama, E; Yonehara, T, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (27.27) | 18.7374 |
| 1990's | 1 (4.55) | 18.2507 |
| 2000's | 7 (31.82) | 29.6817 |
| 2010's | 8 (36.36) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Oh, SJ | 1 |
| Almeida, DF | 1 |
| Villa, SC | 1 |
| de Alarcon, PA | 1 |
| Matthay, KK | 1 |
| London, WB | 1 |
| Naranjo, A | 1 |
| Tenney, SC | 1 |
| Panzer, JA | 1 |
| Hogarty, MD | 1 |
| Park, JR | 1 |
| Maris, JM | 1 |
| Cohn, SL | 1 |
| Kushner, BH | 1 |
| Khakoo, Y | 1 |
| Piffer, S | 1 |
| Turri, G | 1 |
| Acler, M | 1 |
| Richelli, S | 1 |
| Cerini, R | 1 |
| Fiaschi, A | 1 |
| Monaco, S | 1 |
| Bonetti, B | 1 |
| Gauthier, AC | 1 |
| Baehring, JM | 1 |
| Dickmann, JR | 1 |
| Eversheim, F | 1 |
| James, PD | 1 |
| Black, D | 1 |
| Kuper, A | 1 |
| Saibil, F | 1 |
| Battaglia, T | 1 |
| De Grandis, E | 1 |
| Mirabelli-Badenier, M | 1 |
| Boeri, L | 1 |
| Morcaldi, G | 1 |
| Barabino, P | 1 |
| Intra, C | 1 |
| Naselli, F | 1 |
| Pistoia, V | 1 |
| Veneselli, E | 1 |
| Conte, M | 1 |
| Paradas, C | 1 |
| Morgado, Y | 1 |
| Gallardo, E | 1 |
| Juarez, C | 1 |
| Rojas-García, R | 1 |
| Ponseti, JM | 1 |
| Azem, J | 1 |
| Fort, JM | 1 |
| López-Cano, M | 1 |
| Vilallonga, R | 1 |
| Buera, M | 1 |
| Cervera, C | 1 |
| Armengol, M | 1 |
| Mutch, LS | 1 |
| Johnston, DL | 1 |
| Mazzucco, S | 1 |
| Ferrari, S | 1 |
| Mezzina, C | 1 |
| Tomelleri, G | 1 |
| Bertolasi, L | 1 |
| Rizzuto, N | 1 |
| Trautmann, F | 1 |
| Krämer, G | 1 |
| Poralla, T | 1 |
| Eckhardt, R | 1 |
| Arnold, W | 1 |
| Meyer zum Büschenfelde, KH | 1 |
| Villalobos Chaves, F | 1 |
| Casado Chocán, JL | 1 |
| Moreno Rojas, A | 1 |
| Serrano Castro, V | 1 |
| Maslovsky, I | 1 |
| Volchek, L | 1 |
| Blumental, R | 1 |
| Ducach, A | 1 |
| Lugassy, G | 1 |
| Tashima, K | 1 |
| Uyama, E | 1 |
| Hashimoto, Y | 1 |
| Yonehara, T | 1 |
| Uchino, M | 1 |
| Yeshurun, M | 1 |
| Marsot Dupuch, K | 1 |
| Shapira, Y | 1 |
| Cederbaum, SD | 1 |
| Cancilla, PA | 1 |
| Nielsen, D | 1 |
| Lippe, BM | 1 |
| Fierer, J | 1 |
| Bazely, P | 1 |
| Braude, AI | 1 |
| Govindaraj, M | 1 |
| Piro, AJ | 1 |
| Wilson, RE | 1 |
| Hall, TC | 1 |
| Aliapoulios, MA | 1 |
| Nevinny, HB | 1 |
| Moore, FD | 1 |
| Blain, JG | 1 |
| Riley, W | 1 |
| Logothetis, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III Randomized Trial of Intravenous Gammaglobulin Therapy for Patients With Neuroblastoma Associated Opsoclonus-Myoclonus-Ataxia Syndrome Treated With Chemotherapy and Prednisone[NCT00033293] | Phase 3 | 53 participants (Actual) | Interventional | 2004-03-15 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The Bayley Scales of infant development mental scale best score of two time points will be used in the analysis. For a given patient, this score will be used to calculate the change from baseline." (NCT00033293)
Timeframe: Changes from baseline to the better of 6 months or 1 year
| Intervention | Change in Bayley's score (Mean) |
|---|---|
| Arm I (Chemotherapy, Immunoglobulin Therapy) | 117.5 |
| Arm II (Chemotherapy, Observation) | 100.75 |
"The best score at the two time points will be used in this analysis. For a given patient, this best score will be used to calculate the change from baseline. The mean change from baseline for each treatment group will be calculated." (NCT00033293)
Timeframe: Changes from baseline to the better of 6 months or 1 year
| Intervention | Change in VABS score (Mean) |
|---|---|
| Arm I (Chemotherapy, Immunoglobulin Therapy) | 84.53 |
| Arm II (Chemotherapy, Observation) | 144.73 |
A multi-stage design followed by a test of proportions between the treatment arms (chemo vs. chemo + therapeutic immune globulin (IVIG)) will be performed. The first stage of the multi-stage design will also function as an early stopping rule for insufficient activity of chemotherapy in OMA. (NCT00033293)
Timeframe: Changes from baseline to 2 months, 6 months, and 1 year
| Intervention | participants (Number) |
|---|---|
| Arm I (Chemotherapy, Immunoglobulin Therapy) | 21 |
| Arm II (Chemotherapy, Observation) | 11 |
EFS rate for neuroblastoma event from time of study enrollment. (NCT00033293)
Timeframe: Up to 3 years
| Intervention | 3 year EFS (Number) |
|---|---|
| Arm I (Chemotherapy, Immunoglobulin Therapy) | 92.3 |
| Arm II (Chemotherapy, Observation) | 96.0 |
OS rate from time of study enrollment. (NCT00033293)
Timeframe: Up to 3 years
| Intervention | 3 year OS (Number) |
|---|---|
| Arm I (Chemotherapy, Immunoglobulin Therapy) | 100 |
| Arm II (Chemotherapy, Observation) | 96.0 |
2 trials available for prednisone and Ataxia
| Article | Year |
|---|---|
Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial.
Topics: Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Ataxia; Child; Child, Pres | 2018 |
Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Ataxia; Autoantibodies; Cyclos | 2005 |
20 other studies available for prednisone and Ataxia
| Article | Year |
|---|---|
Monosialosyl Antibody in a Case Mimicking CANOMAD Syndrome.
Topics: Adult; Anemia, Hemolytic, Autoimmune; Anti-Inflammatory Agents; Ataxia; Autoantibodies; Autoantigens | 2019 |
Enigmatic entities: opsoclonus myoclonus ataxia syndrome linked to neuroblastoma.
Topics: Ataxia; Child; Humans; Immunoglobulins, Intravenous; Neuroblastoma; Opsoclonus-Myoclonus Syndrome; P | 2018 |
Paroxysmal dysarthria-ataxia in remitting-relapsing Bickerstaff's-like encephalitis.
Topics: Aged; Ataxia; Autoimmune Diseases of the Nervous System; Brain Stem; Dysarthria; Encephalitis; Femal | 2014 |
Hashimoto's encephalopathy mimicking Creutzfeldt-Jakob disease.
Topics: Anti-Inflammatory Agents; Ataxia; Cognition Disorders; Confusion; Creutzfeldt-Jakob Syndrome; Diagno | 2017 |
Steroid responsive psychotic depression.
Topics: Anti-Inflammatory Agents; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Ataxia; Benzodiaze | 2009 |
D-lactic acidosis and ataxia in a man with Crohn disease.
Topics: Acidosis, Lactic; Anti-Inflammatory Agents; Antidiarrheals; Ataxia; Crohn Disease; Diagnosis, Differ | 2010 |
Response to rituximab in 3 children with opsoclonus-myoclonus syndrome resistant to conventional treatments.
Topics: Adrenocorticotropic Hormone; Anti-Inflammatory Agents; Antibodies, Monoclonal, Murine-Derived; Ataxi | 2012 |
Prednisone can worsen ataxic neuropathy with anti-disialosyl IgM antibodies.
Topics: Antigens, Surface; Ataxia; Humans; Immunoglobulin M; Male; Middle Aged; Oligosaccharides; Polyneurop | 2011 |
Late presentation of opsoclonus-myoclonus-ataxia syndrome in a child with stage 4S neuroblastoma.
Topics: Ataxia; Humans; Immunoglobulins, Intravenous; Infant; Male; Neuroblastoma; Paraneoplastic Syndromes, | 2005 |
Hyperpyrexia-triggered relapses in an unusual case of ataxic chronic inflammatory demyelinating polyradiculoneuropathy.
Topics: Anti-Inflammatory Agents; Ataxia; Electromyography; Fever; Humans; Immunoglobulins, Intravenous; Imm | 2006 |
[Systemic lupus erythematosus. Brown-Sequard syndrome, spinal ataxia and peripheral polyneuropathy as the sole manifestations].
Topics: Aged; Antibodies, Antinuclear; Ataxia; Autoantibodies; Azathioprine; DNA; Female; Humans; Liver Cirr | 1984 |
[Miller-Fisher syndrome and encephalitis of the brain stem].
Topics: Ataxia; Brain Stem; Child; Electroencephalography; Electromyography; Encephalitis; Facial Paralysis; | 1995 |
Persistent paraneoplastic neurologic syndrome after successful therapy of Hodgkin's disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Ataxia; Bleomycin; Combined Modality Therapy; | 2001 |
Susac's syndrome: beneficial effects of corticosteroid therapy in a Japanese case.
Topics: Adult; Anti-Inflammatory Agents; Asian People; Asthma; Ataxia; Brain; Cognition Disorders; Confusion | 2001 |
Acute cerebellar syndrome following intermediate-dose cytarabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ataxia; Brain; Cisp | 2001 |
Familial poliodystrophy, mitochondrial myopathy, and lactate acidemia.
Topics: Adolescent; Ataxia; Cerebral Cortex; Child; Child, Preschool; Diazepam; Diffuse Cerebral Sclerosis o | 1975 |
Herpes B virus encephalomyelitis presenting as ophthalmic zoster. A possible latent infection reactivated.
Topics: Animals; Antibodies; Aphasia; Ataxia; Cerebrospinal Fluid Proteins; Cytarabine; Diagnosis, Different | 1973 |
Multiple-drug reactions in tuberculosis--an illustrative case.
Topics: Adult; Agranulocytosis; Aminosalicylic Acids; Antitubercular Agents; Ataxia; Cycloserine; Deafness; | 1968 |
Toxicity studies of fluorouracil used with adrenalectomy in breast cancer.
Topics: Adrenalectomy; Adult; Aged; Alopecia; Ataxia; Blood Platelet Disorders; Breast Neoplasms; Diarrhea; | 1972 |
Optic nerve manifestations of sarcoidosis.
Topics: Adult; Ataxia; Facial Paralysis; Female; Humans; Middle Aged; Neurologic Manifestations; Optic Atrop | 1965 |